Ky. paraplegic eyes brighter future through education, stem cell procedure – WoodwardNews.net
|
Ky. paraplegic eyes brighter future through education, stem cell procedure
WoodwardNews.net During the same time, the possibility of stem cell treatments offered Guest and his supporters hope, but ultimately didn’t pan out. He decided to pause clinical trials and return to school after watching his brother and cousin graduate from Eastern … |
Hartford Business |
Cromwell’s Biological Industries inks stem–cell training pact with Calif. Institute
Hartford Business Biological Industries’ partner, the Pathways to Stem Cell Science institute, will host early career scientists ranging from high school to college-level students and beyond and provide hands-on experience in culturing human pluripotent stem cells … |
|
Stem cells in plants and animals behave surprisingly similarly
Science Daily Stem cells are a hot topic in medical contexts, especially when it comes to cancer and autoimmune diseases. A stem cell is capable of evolving into several different types of cells and is thus a sort of mother cell to all of the body’s specialised cell … |
FierceBiotech |
Sangamo’s Gene Therapy Gets Pfizer Stamp Of Approval
Seeking Alpha Sangamo’s (NASDAQ:SGMO) bold claim that its hemophilia A gene therapy SB-525 could be best in class has received a boost from an early tie-up with Pfizer (NYSE:PFE). Although the project has yet to enter the clinic, Sangamo believes that it could be … Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-inFierceBiotech Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M dealEndpoints News Pfizer taps Sangamo for hemophilia gene therapyBioPharma Dive BioPharma-Reporter.com –MedCity News –Hemophilia News Today all 121 news articles » |
FierceBiotech |
Sangamo’s Gene Therapy Gets Pfizer Stamp Of Approval
Seeking Alpha Sangamo’s (NASDAQ:SGMO) bold claim that its hemophilia A gene therapy SB-525 could be best in class has received a boost from an early tie-up with Pfizer (NYSE:PFE). Although the project has yet to enter the clinic, Sangamo believes that it could be … Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-inFierceBiotech Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M dealEndpoints News Pfizer taps Sangamo for hemophilia gene therapyBioPharma Dive BioPharma-Reporter.com –MedCity News –Hemophilia News Today all 121 news articles » |
Hartford Business |
Cromwell’s Biological Industries inks stem–cell training pact with Calif. Institute
Hartford Business Biological Industries’ partner, the Pathways to Stem Cell Science institute, will host early career scientists ranging from high school to college-level students and beyond and provide hands-on experience in culturing human pluripotent stem cells … |
PharmaTimes |
Pfizer strikes gene therapy deal with Sangamo
PharmaTimes Pfizer and Sangamo are to collaborate on the commercialisation and development of gene therapy programmes for haemophilia A, including SB-525, one of Sangamo’s four lead product candidates. Sangamo will receive a $70m upfront payment from Pfizer … Pfizer top hemophilia choice, enters Sangamo pact that is valued to $500M-plusBioWorld Online |